MBRX News and Press, Moleculin Biotech Inc. From 05/12/22

Gainers: Cullinan Oncology (CGEM) +21%. Concert Pharmaceuticals (CNCE) +20%. Babylon Holdings BBLN +16%. Blue Water Vaccines (BWV) +14%.  ViewRay (VRAY) +10%. Losers: Eargo (EAR) -24%. Senseonics (SENS) -14%. Ascendis Pharma (ASND) -11%. Evaxion Biotech...

Moleculin Biotech press release (NASDAQ:MBRX): Q1 GAAP EPS of -$0.24 misses by $0.01. The Company ended the quarter with $66.1 million of cash. The Company believes that this cash is sufficient to meet its projected operating requirements, which include a forecasted increase over its current ...

Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update PR Newswire – Positive advancements, encouraging preclinical and clinical data, and development activity in all three core technologies – – Multiple key cli...

Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19 PR Newswire – Dosing for first-in-human Phase 1a study to evaluate safe...

Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) PR Newswire – Preliminary positive safety and efficacy data from second Phase 1 AML study validate advancem...

Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer PR Newswire Global leader with a distinguished 30-year career in oncology, hematology, and academia with significant contributions in clinical developments in ovarian cancer, lun...

Moleculin Biotech (NASDAQ:MBRX) on Thursday said the U.S. Food and Drug Administration cleared the clinical-stage biotech's application to study its therapy WP1066 for the treatment of recurrent malignant glioma, a common type of tumor that originates in the brain. MBRX now plans to conduct a...

Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma PR Newswire Investigational New Drug (IND) application clearance from FDA opens up potential for additional investigator funded and led clinical studies ...

Moleculin Announces Corporate Rebranding and Launch of New Website PR Newswire Company reiterates commitment to solving some of the toughest challenges in highly resistant cancers and viruses and developing better treatments that can make a real impact in people's live...

/C O R R E C T I O N -- Moleculin Biotech, Inc./ PR Newswire In the news release, Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting, issued 08-Apr-2022 by Moleculin Biotech, Inc. over PR Newswire, we are advised b...